Hemispherx Biopharma Europe Enters Investment Banking Relations with Major European Institutions

BRUSSELS, Belgium (PROTEXT) - Hemispherx Biopharma (Amex: HEB)said today it started the process of a private placement for itssubsidiary HEB-EU. HEB-EU, which has a marketing applicationpending in the European Union (EU) for treatment of ChronicFatigue Syndrome/Myalgic Encephalitis (CFS/ME), was founded todevelop and market certain novel anti-viral products, includingAmpligen(R) for untreatable chronic and life-threatening humanviral disorders. Quadra Invest and Arthur Anderson Corporate Finance Belgiumhave been mandated to organize the private placement. QuadraInvest is the venture capital division of Dexia, one of thelargest Belgian banks. Arthur Anderson Corporate Finance is adivision of Arthur Anderson, a leading professional servicesorganization. In addition, Quadra Invest formally notified HEB-EU that theirgroup would take a percentage of the equity placement into theirown corporate account. Jurgen Ingels of Quadra Invest commented:"This investment opportunity is exciting to us -- namely aproduct on the cusp of commercialization, strong experiencedmanagement, and broad patent coverage into a major untappedpharmaceutical market." Terms of the investment were notdisclosed. William A. Carter, M.D., Chairman of Hemispherx Europecommented: "We think HEB-EU is uniquely situated to capture amajor position in the European pharmaceutical arena, and as aresult, to arouse significant investor interest, both at theinstitutional and individual investor level." Information contained in this news release other thanhistorical information, should be considered forward-looking andis subject to various risk factors and uncertainties. Forinstance, the strategies and operations of Hemispherx involverisks of competition, changing market conditions, changes in lawsand regulations affecting these industries and numerous otherfactors discussed in this release and in the Company's filingswith the Securities and Exchange Commission. Accordingly, actualresults may differ materially from those in any forward-lookingstatements. ots Original Text Service: Hemispherx BiopharmaInternet: http://www.newsaktuell.de Contact: Richard Piani ofHemispherx Biopharma Europe, fax, 331-4624-8075, or William A.Carter, M.D., CEO of Hemispherx Biopharma U.S., 215-988-0080; orJurgen Ingels of Quadra Invest, fax, 322-222-8308; or Finance -Dries Bossuyt, fax, 322-545-3199, or Investors - Diane Will, 214-954-9300, fax, 214-954-9333, both of Arthur Anderson Corp. Website: http://www.hemispherx.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT